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Measurement of urinary beta core fragment of human chorionic
gonadotrophin in women with vulvovaginal malignancy and its prognostic
significance
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S_qy Tumours of the vulva and vagina are rare and there are relatively few studies of circulating
markers in these conditions. The urinary meas t of the core fragment of the s-subunit of bCG has been
proposed as a usefl tumour marker in non-trophoblastic ynaecological malignancies. This study describes
the measurement of urinary P-core in 50 paents with vulvovaginal malignancy. In contrast to other studis,
corrections were made for both the effect of urie concentration and the age of the patienL Each patint was
followed up for at least 24 months, and at this time their status was correlated with their initial level of
urinary P-core. The senstnivty of P-core was only 38%, but of those patients with elevated kvels 90% had died
within 24 months, while only 32% of those with nomal levels had died. For both patients at initial
presentation and those with recurrent disease there was a highly significant difference in the survival curves
betwn those with devated P-core kvs and those with normal kves. This is similar to findings in cvical
carcmoma, and suggets that for lower genital tract cancer the meaurement of unary P-core may be valuable
as a prognostc indicator, allowing a more informed aproac to treatment and folow-up.
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Vulva tumours are rare, constituting only 3% of all female
malignancies. Fewer than 1000 cases present annually in the
UK, and this is ted in the paucity of studies on markers
of vulval malignancy. Of the cirulating tumour markers,
elevated levels of CA 125 have been reported in 14% of
vulval tumours (Niloff et al., 1984), of squamous cell car-
cinoma antigen (SCC) in 26% of cases (Van der Sijde et al.,
1989) and of carcinoembryonic antigen (CEA) in 33-57% of
cases (Di Saia et al., 1977; Donaldson et al., 1980). Human
chorionic gonadotrophin (hCG) has been detected in the
serum of 10% of women with vulval tmours (Hussa, 1987).
The renal metabolite of the a-subunit of hCG, known as
P-core fragment, can be detected in the urine of women with
non-trophoblastic gynaecological malignancies and has been
proposed as a useful tumour marker (Cole et al., 1988; Nam
et al., 1990a). Relatively little attention has been given to
vulvovaginal tumours, although elevated levels of -core were
detected in four out of eight patients with vulval malignancy
(Nam et al., 1990b).
Most previous studies on urinary a-core fragment have not
taken into account the effect of urine concentration or the
problem of cross-reactivity of most assays with lutinising
hormone (LH). The latter is elevated in pen- and post-
menopausal women and also has been shown to gradually
decrease with increasing number of years in the post-
menopausal state (Chakavarti et al., 1976). It is women in
these age groups who are most at risk of developing vulval
and vaginal tumours. Previous work in our unit has pointed
to the presence of a virtually identical molcule to S-core
known as LH core (Iles et al., 1992). The assay used is
known to cross-react with LH core. However, the exact level
of this cross-reaction is impossible to determine in the
absence of purified LH core standards. To address these
problems, the present study analysed urinary levels of S-core
after correction for urine concentration by measurement of
the urinary concentration of creatinine. Furthermore, since
there is a gradual increase in urinary a-core with increasng
age, the cut-off levels for separation of normal and abnormal
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results were based upon the 90th centile of control groups
according to age.
Patiems an o
The study involved 50 women with vulval or vaginal tumours
referred to the unit between 1990 and 1992. After their
treatment, all were followed for a minimum of 24 months.
Forty women had vulval tumours, of which 23 were initial
presentations and 17 were recurrent disease; ten had vaginal
tumours, of which six were initial presentations and four
were recurrent di . The histology and stage of each
tumour are shown in Table I.
Each patient gave a random urine specimen which was
assayed for a-core fragment by radioimmunoassay using the
S504 antibody (Polyclonal Antibodies, Blaenwaen Farm,
LlandysuL Dyfed, Waks) (Lee et al., 1991). Beta-core
isolated from crude urinary hCG was used for standards and
tracer, the material was calibrated against the matenal
isolated by Bithe et al. (1988). The minimum detection limit
of the assay as defined by the lowest concentration of P-ore
which could be distinguished from the zero standard was
0.025 ng ml-'. Intra-assay variation was 2-10% and inter-
assay variation was 2-11% for concentrations between 0.1
and 5.31 ng ml-' -core. Cross-reactivity with free P-subunit
was kss than 0.7%.
Urine creatinine concentration was measured by the Jaffe
method using a Monarch 200 centrifugal analyser; the result
was expressed in millimoles per litre.
The cut-off levels used were determined from a previous
Table I Stage and histology of 50 patients with vulvovainal
twmours
Stage
I II III IV
Squamous cel carcinoma 10 9 15 3
Adenocarcinoma 1 1 0 0
Adenosquamous carcuinoma I 0 0 0
Melanoma 5 0 0 2
Leiomyosarcoma I 1 1 0
Urinay A4e in vuv tumours and
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study in our unit of urinary Srcore levels corrected for
creatinine in 434 women with no evidence of malignant
disease (PG Carter et al., unpublished data). The control
group was subdivided according to age. The upper limits of
Score levels were the 90th centiles of each group:
40 -49 years (n= 81) 0.044ngmlV'mmol ' creatinine
50- 59 years (n = 74) 0.064 ng ml1mmol ' creatinine
60 -69 years (n = 82) 0.088 ng ml' mmol-' creatinine
70-79 years (n=61) 0.096ngml-'mmol-' creatinine
>80 years (n=65) 0.103ngml-'mmol-' creatinine
All patients were followed for a minimum of 24 months
and their status at this stage was recorded. The percentage
survival for those with elevated Score levels was compared
with those with normal Score levels using a stage corrected
log-rank test and survival tables were constructed using the
Kaplan-Meier method. In addition. the effect of age, stage,
histological type and grade of tumour were examined using
Cox's multivariate analysis. Patients with recurrent disease
were analysed separately from those with initial presentation
disease.
Results
Of the 50 patients in the study 19 (38%) had elevated levels
of corrected core, seven of which were initial presentations
and 12 were recurrent disease. Figure 1 shows the present
status of the patients according to their s-ore levels. Seven-
teen (90%) of the patients with elevated levels had died
within 2 years, six from the initial presentation group and 11
from the recurrent disease group (Table II). Of the 31 (62%)
patients with non-elevated aore levels, 20 were from the
initial presentation group and 11 from the recurrent disease
group. Twenty-one (68%) of these patients are still alive and
comprise 15 from the initial presentation group and six from
the recurrent disease group (Table II). In six patients the
process of correcting for creatinine resulted in the conversion
of the -core level from normal to elevated, and of these five
had died. Conversely, there were three patients were crea-
tinine correction produced a conversion from elevated to
normal, and two of these had died. Thus, with regard to
prognosis, of the nine patients in whom a shift occurred, the
corrected s-core status correlated with the status of the
patient at 24 months in six (67%) cases.
Subdivision of the patients according to stage of disease
yielded very small groups. However, for each stage of
disease, if the sore was elevated, the number of patients
who had died was greater than the number of those still alive
(Table III). With increasing stage of disease the proportion
of deaths increased such that for stage II, III and IV disease
all patients with raised -core levels had died. Conversely, for
patients with stage I and II disease and normal levels of
sore, 85% and 75% respectively were still alive at 24
months. However, for patients with stage III and IV disease
and normal levels of a-core, only 50% and 25% respectively
were still alive at 24 months.
The median value of corrected S-core for those patients
who had died (n = 27) was 0.064 ng ml1' mmol ' creatinine,
and that for those patients still alive (n = 23) was 0.05 ng
ml- ' mmol-' creatinine (P = 0.0205 using the Mann-
Whitney test).
Figures 2 and 3 show the stage-corrected survival curves
for patients tested at initial presentation and with recurrent
disease. In both groups patients with elevated i-core levels
had reduced survival times when compared with those with
normal levels of S-core. The difference is more pronounced in
the initial presentation group (log-rank chi-square = 8.52,
P = 0.0035) than in the recurrent disease group (log-rank
chi-square = 6.059, P = 0.0138). Cox's multivariate analysis
demonstrated a significant relationship between survival and
S-core level (P= 0.007) and stage (P= 0.005), but not for
age, histological type or grade. Furthermore, there was no
significant relationship between those who had initial presen-
tation disease or recurrent disease. Two patients who
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Figure I Status at 24 months of 50 women with vulvovaginal
malignancy according to unnary S-core level. =I] Alive; B.
dead.
Table II Status after 24 months of 50 women with vulvovaginal
tumours
Positive srcore Negative s-core(n=J9) (%) (n=31) (%)
Alive Dead Alive Dead
Initial presentation 1 (5) 6 (32) 15 (48.5) 5 (16)
(n = 27)
Recurrent disease 1 (5) 11 (58) 6 (19.5) 5 (16)
(n = 23)
Total 2 (10) 17 (90) 21 (68) 10 (32)
Tabl III Status of 50 patients with vulvovaginal tumours according to
corrected urinary S-core level and stage of disease
Positive S-core (%) Negative S-core (%}
Stage Alive Dead Alive Dead Total
I 2 (40) 3 (60) 11 (85) 2 (15) 18
II 0 (0) 3 (100) 6 (75) 2 (25) 11
III 0 (0) 10 (100) 3 (50) 3 (50) 16
IV 0 (0) 1 (100) 1 (25) 3 (75) 5
developed recurrent disease during the study were counted in
both the initial presentation and recurrent disease groups.
E iscusi
The S-core fragment of hCG in urine has been proposed as a
useful marker in cases of non-trophoblastic gynaecological
malignancy (Cole et al., 1988; Nam et al., 1990a). One of the
clinical criteria for such a marker is the ability to identify
disease in symptomatic patients. In this respect, our earlier
studies (Lee et al., 1992; Neven et al., 1993) were less promis-
ing than those of others. In the case of vulvovaginal tumours
the overall sensitivity in the present study was 38% (31% at
initial presentation and 47.5% for those with recurrent
disease). These results are similar to those of Nam et al.
(1990b) who reported a sensitivity of 50%.
Although for gynaecological malignancies in general the
sensitivity of S-core in our laboratory appears to be less than
that reported by others, we have found that in cases of
cervical tumours (and bladder tumours), a-core may be of
considerable value as a prognostic marker (Carter et al.,
1994; R lIes et al., unpublished data). The present report
demonstrates the same phenomenon in cases of vulvovaginal
tumours in that 90% of patients with elevated a-ore levels
had died within 24 months of sample collection while 68% of
those with normal levels were still alive after the same period.
The percentage of patients with elevated levels of S-core who
had died was similar for women at initial presentation and
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ing to P-core level.
those with recurrent disease (42% and 47.5% respectively).
In patients with normal -core levels, the correlation of
normal levels with survival was better for those at initial
presentation than for those with recurrent diseas (48.5%
and 19.5% respectively).
All patients wtih stage II, III and IV disease who had
elevated 0-core levels had died within 24 months. The con-
verse aspect (patients with normal a-core levels who are alive
at 24 months) showed good correlation for stage I and II
disease (85% and 75% respectively), though less so for more
advanced stage disease (50% and 25% for stages III and IV).
As with cervial carcinoma, the survival curves for women
at both initial presentation and recurrent disease show
reduced survival if S-core levels were elevated (Figures 2 and
3). Furthermore, for both vulvovaginal and cervical tumours
the difference between those with elevated levels and normal
levels is less pronounced in patients with recurrent disease.
Not unexpectedly, patients with recurrent disease have a
poor prognosis, but even in these cases the S-core level has
some prognostic value.
Our own studies on a control population of over 400
women revealed that the urinary concentration of creatinine
had more than a 40-fold variation (0.8-34mmoll-1). Fur-
thermore, in individual subjects the -core could vary 6-fold
over a 24 h period, and for these reasons it was felt necessary
to correct for this. With regard to the prognostic significance
of -core, the correction for urinary concentration improves
the correlation between -core level and status after 24
months. Among the patients who had died there were several
with normal levels of uncorrected P-core which became
positive after correction for creatinine, and the converse
applied to some surviving patients with elevated levels.
Tlhis study further emphasi the importance of age as a
potential confounding factor and allows the use of age-
specific cut-off levels. Even though most women in this study
were post-menopausal, there was still a 2-fold difference in
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the cut-off for women aged 50-60 when compared with
those over 80.
Poor prognostic features of vulval carcinoma include
advanced-stage disease, poor differentiation, incomplete sur-
gical excision, positive lymph nodes and early recurren.
The results of this study suggest that the level of urinary
P-core can also serve as a prognostic indicator for both initial
presentation disease and recurrent disease. It is especially
interesting that some patients in this study had been initially
diagnosed 10-20 years earlier and, despite episodes of recur-
rent disease, had normal P-core levels yet within a short time
period of the P-core levels becoming elevated these patients
had died. A possible explanation is that squamous cell
tumours may only secrete hCG into the circulation once the
tumour has invaded local blood vessels and, although this
process may be clinically occult, it is obviously associated
with a poor prognosis.
In conclusion, this study shows that a-core tmesurement m
urine is unlikely to be useful as a diagnostic marker though it
may be a very valuable adjunct to other parameters in the
prognosis of an individual case. From the clinical point of
view there has been a trend in recent years to adopt a more
conservative approach in the extent of surgical treatment for
vulval tumours, though this has to be balanced against the
risks of recurrent disease. Clearly, incrsing the prognostic
information available to the clinician allows improved plan-
ning of both surgial treatment and subsequent follow-up to
detect any recurrent disease at an early stage.
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